GlassScriptPhysician profile
Alexander Rapisarda
NPI 1811994692
$7,039.52
in general payments reported to CMS, 2019-2025
33 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $342 · 2021: $895 · 2022: $1,045 · 2023: $1,264 · 2024: $1,210 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,818 · Education: $26.55 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,817.53 |
| Education | $26.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,710.72 | 2019-2025 | |
| Janssen Biotech, INC. | $777.22 | 2019-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $687.13 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $636.93 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $452.28 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $405.51 | 2019-2025 | |
| Braintree Laboratories, INC. | $355.23 | 2019-2025 | Sutab, Suflave |
| Qol Medical, LLC | $277.09 | 2019-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $262.67 | 2019-2025 | |
| Ardelyx, INC. | $198.29 | 2022-2025 | Ibsrela |
| Celgene Corporation | $173.79 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $170.32 | 2019-2025 | |
| Allergan, INC. | $141.23 | 2019 | |
| Lilly USA, LLC | $119.16 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $111.25 | 2019-2023 | Injectafer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $82.12 | 2024-2025 | Vegzelma |
| Organon LLC | $77.50 | 2023 | Renflexis, Hadlima |
| Ferring Pharmaceuticals INC. | $51.20 | 2021-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $43.24 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $37.17 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $35.64 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $28.79 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $27.72 | 2020 | |
| Phathom Pharmaceuticals, INC. | $26.98 | 2025 | Voquezna |
| Boston Scientific Corporation | $24.88 | 2024 | |
| Sanofi-Aventis U.S. LLC | $20.25 | 2025 | |
| Novo Nordisk INC | $19.91 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $16.88 | 2023 | Idacio |
| Endo Pharmaceuticals INC. | $15.00 | 2020 | |
| Merck Sharp & Dohme LLC | $14.99 | 2021 | |
| Genzyme Corporation | $14.25 | 2022 | |
| Mauna Kea Technologies, INC. | $12.32 | 2024 | |
| Shionogi INC | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Rapisarda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.